ESCMID weekly news 09.06.2020

9 June 2020: ESCMID Weekly News
Having trouble viewing this email? View in your browser.


9 June 2020

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.


ESCMID Webinars on COVID-19 – Catch the replays

Over the last two months, ESCMID has conducted a series of webinars addressing various aspects of COVID-19, including infection control, diagnosis and international perspectives.

You can watch replays of the webinars on the ESCMID E-Academy.

Follow ESCMID on
Twitter or Facebook to stay up to date with the announcement of future webinars.

› Read more

Elections of Study Group Executive Committees

Elections results have been announced for the following Study Groups: ESGARS, ESGCD, EVASG, ESGFOR, EPASG, EFISG, ESGITM, ESGPHM, EFWISG, ESGBOR, ESGCP, ESGIB, ESGIE, ESGMD and ESGS. Elections have closed for ESGCIP, ESGHAMI, ESGLI and ESGAP; the respective Election Committees are currently reviewing the results of the vote.

A run-off ballot has been opened for ESGREV and ESGMYC. Special elections to replace a member of the executive committee have been opened for ESGAI; the election committee is reviewing nominations and will open elections soon.

To participate in the election process, log in to with your ESCMID credentials and click on the “Study Group Elections” icon. Only members with a valid ESCMID membership can take part in the election process; to be able to vote, please be sure to renew immediately your ESCMID membership, should it expire in the coming days.

For any question, contact

› Read more

Via EITaF: COVID-19 News Highlights

The ESCMID Emerging Infections Taskforce (EITaF) has prepared a briefing on several recent COVID-19 related issues.

Topics covered include: the need to be critical when reading all publications, even in the best journals; two prospective studies showing lack of effect of hydroxychloroquine to prevent COVID19 after high risk exposures, and in the treatment of hospitalised patients; the unexplained low prevalence of SARS-CoV-2 antibodies in European countries that have experienced large epidemic curves, and the implications for herd immunity; and the disproportionate risks of acquisition and death from COVID19 among ethnic minority groups, as well as overrepresentation of these groups in children presenting with multisystem inflammatory syndrome.

› Read more


Upcoming GARDP Webinar – June 16, 2020

Don’t miss the next GARDP Live Webinar ‘Bringing new treatments for drug-resistant infections to all who need them’, taking place next Tuesday, 9 June 2020 at 17:00 CEST.

Seamus O’Brien, François Franceschi and Sally Ellis from GARDP will present the webinar, which will be moderated by Laura Piddock.

Register on the GARDP Website.

› Read more


CMI highlight: New onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2

This study presents a retrospective observational analysis of patients with SARS-CoV-2 admitted to hospital or managed in the community and their household contacts across a London population during March 1 - April 1, 2020.

Both symptomatology and duration were extracted from routinely collected clinical data and follow-up telephone consultations and used to investigate the prevalence of anosmia and ageusia in adult patients with a laboratory confirmed diagnosis of severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2).

From the collected data it resulted that over half of positive patients reported anosmia and ageusia, a significant outcome when compared to the prevalence of anosmia and ageusia in other post viral upper respiratory tract infections. The authors conclude that based on these findings, anosmia and ageusia should be added to existing case definitions for SARS-CoV2 and guide self-isolation procedures.

› Read more

ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube

The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.